Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | GAA | P10253 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24731121 | 0.94 | MAPT (0.45) | MAPTGAATDP1RAB9AALDH1A1 | |
| SCHEMBL12698653 | 0.83 | MAPT (0.46) | MAPTGAATDP1RAB9AALDH1A1 | |
| SCHEMBL17613184 | 0.79 | MAPT (0.55) | MAPTGAATDP1RAB9AALDH1A1 | |
| SCHEMBL30204341 | 0.77 | GSTA1 (0.56) | MAPTGAARAB9AALDH1A1KDM4E | |
| SCHEMBL903543 | 0.76 | MAPT (0.43) | MAPTGAATDP1RAB9AALDH1A1 | |
| SCHEMBL3304135 | 0.75 | ALDH2 (0.47) | MAPTGAAHPGDNPC1MEN1 | |
| SCHEMBL2144787 | 0.75 | ALDH2 (0.47) | MAPTGAAHPGDNPC1MEN1 | |
| SCHEMBL3304132 | 0.75 | ALDH2 (0.47) | MAPTGAAHPGDNPC1MEN1 | |
| SCHEMBL1462528 | 0.74 | RAB9A (0.47) | MAPTGAATDP1RAB9AALDH1A1 | |
| SCHEMBL180203 | 0.74 | MAPT (0.61) | MAPTGAATDP1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2621279-B1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170334926-A1 | PROCESS FOR PREPARING SUBSTITUTED INDOLE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9725464-B2 | Process for preparing tetracyclic heterocycle compounds | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170166586-A1 | PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS | MSD R&D (CHINA) CO., LTD (CN) | 2017-06-15 | — | — | US | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20160257698-A1 | PROCESS FOR PREPARING TETRACYCLIC HETEROCYCLE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2016073659-A1 | PROCESS FOR PREPARING SUBSTITUTED INDOLE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015065821-A1 | PROCESS FOR PREPARING TETRACYCLIC HETEROCYCLE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2012050848-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040924-A1 | FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041227-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885GAA 530/4885TDP1 4225/4885 |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885GAA 530/4885TDP1 4225/4885 |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885GAA 530/4885TDP1 4225/4885 |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885GAA 530/4885TDP1 4225/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885GAA 530/4885TDP1 4225/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885GAA 530/4885TDP1 4225/4885 |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, ZC3HAV1L | MAPT 2414/4885GAA 75/4885TDP1 3056/4885 |
| US-20170166586-A1 | PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS | CYP1A2, CYP3A5, CYP1B1 | MAPT 3885/4885GAA 1299/4885TDP1 2287/4885 |
| US-20170334926-A1 | PROCESS FOR PREPARING SUBSTITUTED INDOLE COMPOUNDS | IDO1, IDO2, TPH1 | MAPT 2778/4885GAA 3470/4885TDP1 3224/4885 |
| US-20160257698-A1 | PROCESS FOR PREPARING TETRACYCLIC HETEROCYCLE COMPOUNDS | GTF3C5, HCCS, GTF3C1 | MAPT 3829/4885GAA 385/4885TDP1 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.